Publication:
Antiseizure medication for brain metastasis-related epilepsy: Findings of optimal choice from a retrospective cohort

Simple item page
dc.contributor.authorSánchez-Villalobos, José Manuel
dc.contributor.authorAledo-Serrano, Ángel
dc.contributor.authorSerna-Berna, Alfredo
dc.contributor.authorSalinas-Ramos, Juan
dc.contributor.authorMartínez Alonso, Emma
dc.contributor.authorPérez-Vicente, José Antonio
dc.contributor.authorAlcaraz Baños, Miguel
dc.contributor.departmentBiología Celular e Histología
dc.contributor.otherFacultad de Medicina
dc.date.accessioned2026-02-16T08:22:53Z
dc.date.available2026-02-16T08:22:53Z
dc.date.copyright© 2021 Elsevier B.V.
dc.date.issued2021-11-19
dc.description.abstractObjective: To analyze the prevalence of antiseizure medication (ASM) in patients with brain metastasis-related epilepsy (BMRE) treated with radiosurgery and the relationship between ASM and psychiatric comorbidity. Material and methods: This is a cross-sectional observational design study with retrospective review of medical records of all patients with brain metastases treated with volumetric modulated arc therapy radiosurgery (VMAT-RS) between 2012 and 2018 in a tertiary oncology center. We included those patients with BMRE, analyzing the clinical and demographic data, with special attention to psychiatric comorbidities and the use of ASM. Results: Of the 121 patients with brain metastases included for treatment with VMAT-RS, a total of 38 presented BMRE. The most widely used ASM as first-line treatment was levetiracetam (89%). Only 8% of the patients received sodium channel blockers. The most common psychiatric comorbidity was depression (42.1%). Conclusions: Levetiracetam is the most widely used ASM in patients with BMRE treated with VMAT-RS. Nevertheless, common psychiatric comorbidities in this population might change the decision-making of ASM choice.
dc.formatapplication/pdf
dc.format.extent5
dc.identifier.citationEpilepsy Research 178 (2021) 106812
dc.identifier.doihttps://doi.org/10.1016/J.EPLEPSYRES.2021.106812
dc.identifier.eissn1872-6844
dc.identifier.issn0920-1211
dc.identifier.urihttp://hdl.handle.net/10201/205181
dc.languageeng
dc.publisherElsevier
dc.relationSin financiación externa a la Universidad
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0920121121002679?via%3Dihub
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAntiepileptic drug
dc.subjectSodium channel blockers
dc.subjectSeizure
dc.subjectBrain metastases
dc.subjectVMAT radiosurgery
dc.subjectMood disorder
dc.subject.odsObjetivo 3: Salud
dc.titleAntiseizure medication for brain metastasis-related epilepsy: Findings of optimal choice from a retrospective cohort
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublicationes
relation.isAuthorOfPublication3fd5eb36-2d6e-4f9e-8e3f-fa44f8982697
relation.isAuthorOfPublication2e41afa5-fcbc-4bba-8b0f-6de98bb63713
relation.isAuthorOfPublication.latestForDiscovery3fd5eb36-2d6e-4f9e-8e3f-fa44f8982697
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-2 Sanchez-V‎illalobos et al.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos